Early-stage Alzheimer disease: getting trial-ready
PS Aisen, GA Jimenez-Maggiora, MS Rafii… - Nature Reviews …, 2022 - nature.com
Slowing the progression of Alzheimer disease (AD) might be the greatest unmet medical
need of our time. Although one AD therapeutic has received a controversial accelerated …
need of our time. Although one AD therapeutic has received a controversial accelerated …
[HTML][HTML] Risk factors for severe COVID-19 in children: a systematic review and meta-analysis
JH Choi, SH Choi, KW Yun - Journal of Korean medical …, 2022 - synapse.koreamed.org
Background Coronavirus disease 2019 (COVID-19) has been the most important global
issue since December 2019. Although the clinical course of COVID-19 is known to be milder …
issue since December 2019. Although the clinical course of COVID-19 is known to be milder …
Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells
Down's syndrome (DS) presents with a constellation of cardiac, neurocognitive and growth
impairments. Individuals with DS are also prone to severe infections and autoimmunity …
impairments. Individuals with DS are also prone to severe infections and autoimmunity …
Beschlussentwurf der STIKO zur 4. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung
S Vygen-Bonnet, J Koch, C Bogdan, T Harder… - 2021 - edoc.rki.de
Die STIKO empfiehlt die Impfung gegen COVID-19 mit einem der beiden zugelassenen
mRNA-Impfstoffe (Comirnaty von BioNTech/Pfizer, COVID-19-Vaccine von Moderna) oder …
mRNA-Impfstoffe (Comirnaty von BioNTech/Pfizer, COVID-19-Vaccine von Moderna) oder …
Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome
L Malle, M Martin-Fernandez, S Buta, A Richardson… - Immunity, 2022 - cell.com
Down syndrome (DS) is typically caused by triplication of chromosome 21. Phenotypically,
DS presents with developmental, neurocognitive, and immune features. Epidemiologically …
DS presents with developmental, neurocognitive, and immune features. Epidemiologically …
ACE2 in chronic disease and COVID-19: gene regulation and post-translational modification
CW Wang, HC Chuang, TH Tan - Journal of Biomedical Science, 2023 - Springer
Abstract Angiotensin-converting enzyme 2 (ACE2), a counter regulator of the renin-
angiotensin system, provides protection against several chronic diseases. Besides chronic …
angiotensin system, provides protection against several chronic diseases. Besides chronic …
Opportunities, barriers, and recommendations in Down syndrome research
JA Hendrix, A Amon, L Abbeduto… - … science of rare …, 2021 - journals.sagepub.com
BACKGROUND: Recent advances in medical care have increased life expectancy and
improved the quality of life for people with Down syndrome (DS). These advances are the …
improved the quality of life for people with Down syndrome (DS). These advances are the …
Immunity and inflammation: the neglected key players in congenital heart disease?
LM Wienecke, S Cohen, J Bauersachs, A Mebazaa… - Heart Failure …, 2022 - Springer
Although more than 90% of children born with congenital heart disease (CHD) survive into
adulthood, patients face significantly higher and premature morbidity and mortality. Heart …
adulthood, patients face significantly higher and premature morbidity and mortality. Heart …
DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
Identifying host genes essential for Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) has the potential to reveal novel drug targets and further our understanding …
(SARS-CoV-2) has the potential to reveal novel drug targets and further our understanding …
Immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with down syndrome
The risk of severe outcomes following respiratory tract infections is significantly increased in
individuals over 60 years, especially in those with chronic medical conditions, ie …
individuals over 60 years, especially in those with chronic medical conditions, ie …